New Delhi: From suspiciously cheap medicines and tampered labels to remote rural markets that often escape scrutiny, the Centre has tightened nationwide drug surveillance with revised sampling guidelines aimed at cracking down on spurious and substandard products.The new regulatory guidelines issued by the Central Drugs Standard Control Organization direct drug inspectors to move beyond routine checks focused largely on big brands and urban markets and instead widen surveillance across rural, tribal and border regions.The document warns that poor-quality and fake medicines can lead to treatment failure, adverse reactions, rising antimicrobial resistance and higher healthcare costs, particularly among vulnerable patients.Officials have now been asked to specifically target medicines sold at unusually high discounts, products with tampered labels or suspicious packaging, drugs moving through irregular supply chains and outlets repeatedly linked to “Not of Standard Quality” (NSQ) or spurious products.The guidelines note that drug sampling in many regions had remained random and heavily concentrated around urban locations, leaving medicines reaching distant consumers and smaller distribution chains poorly monitored.For the first time, inspectors have been directed to prepare structured monthly and annual sampling plans covering seasonal disease medicines, government supply chains and underserved regions.The Centre has also ordered creation of a centralised database of outlets repeatedly linked to spurious medicines so that alerts can be publicly shared and stricter monitoring maintained.Under the revised norms, every drug inspector will have to collect at least 10 samples every month, including drugs, cosmetics and medical devices.The guidelines stress faster laboratory testing and quicker public alerts or recalls to stop unsafe medicines from remaining in circulation for long periods. Inspectors have been instructed to send collected samples for testing on the same day or latest by the following day.The revised framework also seeks closer coordination between state and central drug authorities for surveillance, recalls and public alerts related to drugs, cosmetics and medical devices.